Table 1 Summary of chemotherapy regimens... | American Society of Hematology

Table 1

Summary of chemotherapy regimens in the 3 study groups

Treatment characteristics	BFM-86–90 protocols			SFOP protocols		UKCCSG protocols
Treatment characteristics	B-SGR / K1	B-RG / K2	B-IV / K3	HM89	HM91	9001	9002	9003
Total treatment duration, mo	2.5	4	4	8	7	5.3	3.5	5.5
Methotrexate
Dose/injection, g/m²	0.5	0.5	5	3	3	1	3	8
Duration of infusion, h	24	24	24	3	3	3	3	3
Number of courses	3	6	4	6	6	4	5	3
Total doses of other drugs
Cyclophosphamide, g/m²	1.4	3.4	2.4	7.3	10.3	0	5.8	6.8
Ifosfamide, g/m²	8	12	8	0	0	0	0	0
Doxorubicin, mg/m²	50	150	100	360	360	200	180	240
Etoposide, mg/m²	400*	600	1300	1800	1200	0	0	2500
Number of intrathecal injections	4	7	11	0	0	6**	10	10
Steroids	Dexa	Dexa	Dexa	Pred	Pred	Pred	Pred	Pred

Treatment characteristics	BFM-86–90 protocols			SFOP protocols		UKCCSG protocols
Treatment characteristics	B-SGR / K1	B-RG / K2	B-IV / K3	HM89	HM91	9001	9002	9003
Total treatment duration, mo	2.5	4	4	8	7	5.3	3.5	5.5
Methotrexate
Dose/injection, g/m²	0.5	0.5	5	3	3	1	3	8
Duration of infusion, h	24	24	24	3	3	3	3	3
Number of courses	3	6	4	6	6	4	5	3
Total doses of other drugs
Cyclophosphamide, g/m²	1.4	3.4	2.4	7.3	10.3	0	5.8	6.8
Ifosfamide, g/m²	8	12	8	0	0	0	0	0
Doxorubicin, mg/m²	50	150	100	360	360	200	180	240
Etoposide, mg/m²	400*	600	1300	1800	1200	0	0	2500
Number of intrathecal injections	4	7	11	0	0	6**	10	10
Steroids	Dexa	Dexa	Dexa	Pred	Pred	Pred	Pred	Pred

Dexa indicates dexamethasone; and Pred, prednisone.

Teniposide instead of Etoposide in the BFM-86 protocol.

Only for patients with head and neck disease.